{
  "ticker": "IPX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963138",
  "id": "02963138",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250627",
  "time": "1742",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l68znqgsf7jz.pdf",
  "summary": "### **Material Information Summary \u2013 IperionX Limited (Appendix 3Y Notices)**  \n\n#### **Director Todd Hannigan**  \n- **Securities acquired**:  \n  - **141,844 shares** issued as compensation (post-shareholder approval).  \n  - **295,130 RSUs** (vesting by Apr 10, 2028).  \n  - **306,302 performance rights each** at A$6.00, A$7.00, and A$8.00/share (vesting by Apr 10, 2029).  \n\n#### **Director Anastasios Arima**  \n- **Securities acquired**:  \n  - **625,000 shares** via exercise of A$0.20 options (A$125,000 paid).  \n  - **419,910 RSUs** (vesting by Apr 10, 2028).  \n  - **435,806 performance rights each** at A$6.00, A$7.00, and A$8.00/share (vesting by Apr 10, 2029).  \n- **Margin loan facility adjustment**:  \n  - **Additional 300,000 shares** transferred to HSBC Custody as collateral (total collateral now **6.6M shares**). No change in beneficial ownership.  \n\n#### **Key Implications**  \n- **Equity dilution risk**: New RSUs & performance rights (total ~2.1M shares potential) linked to long-term price targets.  \n- **Director liquidity**: Arima\u2019s margin loan facility expanded, indicating potential leverage against holdings.  \n\n*No material trading halt or capital raising details identified.*",
  "usage": {
    "prompt_tokens": 3461,
    "completion_tokens": 345,
    "total_tokens": 3806,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-27T07:57:38.067823"
}